HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies
Multiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarge...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2018 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (171 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993548068304498 |
---|---|
ctrlnum |
(CKB)4920000000094149 (oapen)https://directory.doabooks.org/handle/20.500.12854/49485 (EXLCZ)994920000000094149 |
collection |
bib_alma |
record_format |
marc |
spelling |
Francesca Chiodi auth HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies Frontiers Media SA 2018 1 electronic resource (171 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Multiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarged during HIV-1 infection. Antibodies with the capacity to neutralize a broad range of HIV-1 isolates can be detected only in a minority of infected patients, after a year or more from acute infection. An open question is whether the inability of producing neutralizing HIV-1 antibodies is somehow linked to the B cell immunopathology observed in patients. In this research topic we invited scientists to summarize the current state of knowledge on regulation and development of B cells and antibody responses during HIV-1 infection; fifteen contributions were received comprising both reviews and original articles. The articles are related to B cell dysfunctions identified in HIV-1 infected individuals, production of different types of antibodies (neutralizing versus non neutralizing, and of different isotypes) in vivo during HIV-1 infection and the biological factors which may impact on this process, clinical potential and applications of anti-HIV antibodies and how to achieve neutralizing antibody responses to HIV-1 epitopes upon vaccination. The topic has gathered articles on front-line research undertaken in the field of B cells and antibodies in HIV-1 infection. It is our hope that the collection of articles presented in this book may be useful for new and experienced scholars in the field and add a piece to the complex puzzle of knowledge needed for the development of an HIV-1 vaccine. English auto-antibodies to CCR5 BAFF Gene Expression clinical potential of HIV-1 antibodies mucosal IgA responses FcRL4 neutralizing and non neutralizing HIV-1 antibodies HIV-1 vaccine targets B cells CXCL13 maternal HIV antibodies 2-88945-461-4 Gabriella Scarlatti auth |
language |
English |
format |
eBook |
author |
Francesca Chiodi |
spellingShingle |
Francesca Chiodi HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies Frontiers Research Topics |
author_facet |
Francesca Chiodi Gabriella Scarlatti |
author_variant |
f c fc |
author2 |
Gabriella Scarlatti |
author2_variant |
g s gs |
author_sort |
Francesca Chiodi |
title |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
title_full |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
title_fullStr |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
title_full_unstemmed |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
title_auth |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
title_new |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
title_sort |
hiv-induced damage of b cells and production of hiv neutralizing antibodies |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2018 |
physical |
1 electronic resource (171 p.) |
isbn |
2-88945-461-4 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT francescachiodi hivinduceddamageofbcellsandproductionofhivneutralizingantibodies AT gabriellascarlatti hivinduceddamageofbcellsandproductionofhivneutralizingantibodies |
status_str |
n |
ids_txt_mv |
(CKB)4920000000094149 (oapen)https://directory.doabooks.org/handle/20.500.12854/49485 (EXLCZ)994920000000094149 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787551946615291904 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02961nam-a2200409z--4500</leader><controlfield tag="001">993548068304498</controlfield><controlfield tag="005">20231214132837.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094149</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/49485</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094149</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Francesca Chiodi</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (171 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Multiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarged during HIV-1 infection. Antibodies with the capacity to neutralize a broad range of HIV-1 isolates can be detected only in a minority of infected patients, after a year or more from acute infection. An open question is whether the inability of producing neutralizing HIV-1 antibodies is somehow linked to the B cell immunopathology observed in patients. In this research topic we invited scientists to summarize the current state of knowledge on regulation and development of B cells and antibody responses during HIV-1 infection; fifteen contributions were received comprising both reviews and original articles. The articles are related to B cell dysfunctions identified in HIV-1 infected individuals, production of different types of antibodies (neutralizing versus non neutralizing, and of different isotypes) in vivo during HIV-1 infection and the biological factors which may impact on this process, clinical potential and applications of anti-HIV antibodies and how to achieve neutralizing antibody responses to HIV-1 epitopes upon vaccination. The topic has gathered articles on front-line research undertaken in the field of B cells and antibodies in HIV-1 infection. It is our hope that the collection of articles presented in this book may be useful for new and experienced scholars in the field and add a piece to the complex puzzle of knowledge needed for the development of an HIV-1 vaccine.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">auto-antibodies to CCR5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BAFF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Gene Expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical potential of HIV-1 antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mucosal IgA responses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FcRL4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neutralizing and non neutralizing HIV-1 antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HIV-1 vaccine targets</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CXCL13</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">maternal HIV antibodies</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-461-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gabriella Scarlatti</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:33:30 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338723070004498&Force_direct=true</subfield><subfield code="Z">5338723070004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338723070004498</subfield></datafield></record></collection> |